Zanubrutinib for the treatment of MYD88 wild-type Waldenstr�m macroglobulinemia: a substudy of the phase 3 ASPEN trial

Citation

Dimopoulos, M, Garcia-Sanz, R, Lee, H et al. 2020, 'Zanubrutinib for the treatment of MYD88 wild-type Waldenstr�m macroglobulinemia: a substudy of the phase 3 ASPEN trial', Blood Advances, vol. 4, no. 23, pp. 6009-6018.

Year

2020

Updated:  18 July 2024 / Responsible Officer:  Director (Research Services Division) / Page Contact:  Researchers